熱門資訊> 正文
Candel Therapeutics宣布直接发行1500万美元
2025-06-24 21:19
- Candel Therapeutics (NASDAQ:CADL) is selling ~3.2M shares at $4.67 each in a registered direct offering.
- The offering is expected to close on June 25, 2025, with gross proceeds of around $15M before expenses.
- Investors include healthcare-focused institutions, company executives, and board members.
- Funds will support pre-commercialization and launch readiness for CAN-2409 in prostate cancer, pending regulatory approval.
- Proceeds will also be used for medical affairs, BLA preparation expected in Q4 2026, and general corporate purposes.
- Source: Press release
More on Candel Therapeutics
- Candel Therapeutics: CAN-2409's Promising Progress Deserves An Upgrade
- Candel gains after FDA RMT designation for lead asset
- Candel Therapeutics GAAP EPS of $0.13
- Seeking Alpha’s Quant Rating on Candel Therapeutics
- Historical earnings data for Candel Therapeutics
推薦文章
華盛早報丨重大突破！三大加密貨幣法案眾議院闖關成功；美聯儲，降息大消息
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
美股機會日報 | 6月零售數據高於市場預期；臺積電績后漲超3%
美股「七巨頭」迎特朗普關稅后首次大考！Q2能否交出亮眼成績單，繼續引領美股上漲？
華盛早報丨TACO交易再現！特朗普閃電改口「解僱鮑威爾」；美國眾議院加密貨幣立法進程受阻
財報前瞻 | 特斯拉Q2營收料下滑10%！股價銷量雙殺下，馬斯克能否逆轉局勢？
美股機會日報 | 低於市場預期！美國6月PPI同比增長2.3%；特斯拉官宣Model Y L
華盛早報丨事關中美關税！美財長最新放風；「加密周」突發！多項加密貨幣法案遭眾議院否決
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
